Pitavastatin Sitotoksisitesinin Serviks Kanser Hücre (Hela) Hattında Değerlendirilmesi
xmlui.mirage2.itemSummaryView.MetaDataShow full item record
Cervical cancer which is one of the most common cancer types in women throughout the world. Investigation of possible and alternative treatment methods of cervical cancer will lead to the discovery of new effective treatment options for patients by increasing knowledge about progress of this disease. Therefore, the aim of this thesis is to investigate the potential anticancer effect of pitavastatin in human cervical cancer cell line (HeLa). In addition, the possible cytotoxic effect of the combination of pitavastatin and cisplatin, which is conventional cervical cancer treatment drug, was assessed. In this study the effect of pitavastatin and cisplatin in cell viability were determined via 3-(4.5-Dimethylthiazol-2-yl)-2.5-Diphenyltetrazolium Bromide (MTT) test and neutral red uptake (NRU) assays. The action profiles of different concentrations on cell growth curves have been evaluated and the half maximal inhibitory concentration (IC50) values have been calculated. The possible cytotoxic effects of pitavastatin administered separately and in combination with cisplatin in HeLa cell line have been investigated by this thesis for the first time. It has been shown that pitavastatin has a marked cytotoxic effect in HeLa cells at a concentration range of 2 μM - 200 μM and cisplatin decreases cell viability due to increased dose by MTT and NRU assays. Treatment with combined pitavastatin and cisplatin at multiple doses resulted in significantly greater inhibition of proliferation than any other single dose. The findings suggest that, pitavastatin alone or in combination with cisplatin may be a promising strategy for cervical cancer treatment.